Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | USP2 | O75604 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335615 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8966804 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18975256 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL135863 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23014949 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL128978 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL23014965 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL130671 | 1.00 | — | — | |
| SCHEMBL130493 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8907249 | 1.00 | HSD17B10 (0.50) | HSD17B10MAPTCYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2024-10-31 | — | — | US | disclosed |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | EMORY UNIVERSITY (US) | 2024-07-30 | — | — | US | disclosed |
| US-20240043467-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2024-02-08 | — | — | US | disclosed |
| EP-4204428-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | Emory University (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116368143-A | Nucleoside 5' -substituted monophosphates, prodrugs thereof, and uses thereof | 埃莫里大学 | 2023-06-30 | — | — | CN | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | UNIV EMORY (US) | 2022-09-22 | — | — | US | disclosed |
| EP-4017499-A1 | NUCLEOSIDE PRODRUGS AND USES RELATED THERETO | Emory University (US) | 2022-06-29 | — | — | EP | disclosed |
| US-11365183-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2022-06-21 | — | — | US | disclosed |
| CN-114502172-A | Nucleoside prodrugs and related uses thereof | 爱默蕾大学 | 2022-05-13 | — | — | CN | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-12-23 | — | — | US | disclosed |
| US-20040039212-A1 | Sphingolipid derivatives and their methods of use | LIOTTA DENNIS C (US) | 2004-02-26 | — | — | US | disclosed |
| EP-1352650-A1 | INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES | Institute of Medicinal Molecular Design, Inc. (JP) | 2003-10-15 | — | — | EP | disclosed |
| US-6610835-B1 | Compound of given formula; use for treatment of abnormal cell proliferation, tumors, inflammation, psoriasis, inflammatory bowel disease; promotion of cell differentiation, induction of apoptosis, inhibition of protein kinase C | EMORY UNIVERSITY | 2003-08-26 | — | — | US | disclosed |
| EP-1053243-A1 | SPHINGOLIPID DERIVATIVES AND THEIR METHODS OF USE | EMORY UNIVERSITY (US) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999041266-A9 | SPHINGOLIPID DERIVATIVES AND THEIR METHODS OF USE | UNIV EMORY (US) | 2000-11-16 | — | — | WO | disclosed |
| WO-1999041266-A1 | SPHINGOLIPID DERIVATIVES AND THEIR METHODS OF USE | EMORY UNIVERSITY (US) | 1999-08-19 | — | — | WO | disclosed |
| US-4440940-A | HYPOLIPIDEMIC AND ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298185-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | HSD17B10 322/4885MAPT 4429/4885CYP1A2 38/4885 |
| US-20240360163-A1 | Nucleoside Prodrugs and Uses Related Thereto | PNPO, GSTO1, CYP2C18 | HSD17B10 322/4885MAPT 4429/4885CYP1A2 38/4885 |
| US-12049474-B2 | Nucleoside prodrugs and uses related thereto | PNPO, GSTO1, CYP2C18 | HSD17B10 322/4885MAPT 4429/4885CYP1A2 38/4885 |
| US-11365183-B2 | Eicosanoid derivatives | FABP3, PTGER3, PTGES3 | HSD17B10 339/4885MAPT 4861/4885CYP1A2 132/4885 |
| US-20040039212-A1 | Sphingolipid derivatives and their methods of use | SPHK2, SMPD2, SPHK1 | HSD17B10 1052/4885MAPT 3762/4885CYP1A2 444/4885 |
| US-20240043467-A1 | 5'-SUBSTITUTED NUCLEOSIDE MONOPHOSPHATES, PRODRUGS THEREOF, AND USES RELATED THERETO | PNP, ENTPD5, TYMP | HSD17B10 2380/4885MAPT 4741/4885CYP1A2 1344/4885 |
| US-20040259877-A1 | Inhibitors against the production and release of inflammatory cytokines | NFKBIA, IL1B, IKBKB | HSD17B10 704/4885MAPT 2435/4885CYP1A2 1483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.